NCT03595657 · OUTCOME

6-month Overall Survival (OS) Rate

A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) · Source last updated 2024-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Analysis population: One patient was excluded from the efficacy analysis set because the patient was not confirmed as ENKTL by central pathology.

Groups in this outcome

Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
R/R ENKTL	79

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
R/R ENKTL	79.2	Not reported	68.3	86.7	Not reported

Complete source fields

classes

denoms

dispersion Type

95% Confidence Interval

groups

param Type

NUMBER

population Description

One patient was excluded from the efficacy analysis set because the patient was not confirmed as ENKTL by central pathology.

reporting Status

POSTED

time Frame

6 months

title

6-month Overall Survival (OS) Rate

type

OTHER_PRE_SPECIFIED

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice